Quince Therapeutics Overview
Quince Therapeutics (QNCX) has a ROE of 261.79%, above the Healthcare sector average of -100.59%.
Get informed when a big investor buys or sells
+ Follow261.79%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, QNCX shows a ROE of 261.79%. That is above the Healthcare sector average of -100.59%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about -100.59%. Quince Therapeutics is at 261.79%, which is higher that average. That is roughly 360.3% above the sector mean. Use the comparison chart on this page to see how QNCX stacks up against individual peers as well.
Check the historical chart to see whether QNCX's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Quince Therapeutics with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has Quince Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 261.79%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about -100.59%, while QNCX is at 261.79%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
